Skip to main content

A dose response analysis of a specific bone marrow concentrate treatment protocol for knee osteoarthritis



Prior studies describing the treatment of symptomatic knee osteoarthritis with injections of bone marrow concentrate have provided encouraging results. The relationship between the cellular dose contained within the bone marrow concentrate and efficacy of the treatment, however, is unclear. In the present study we describe clinical outcomes for symptomatic knee osteoarthritis in relation to higher and lower cell concentrations contained within a bone marrow concentrate treatment protocol.


Data from an ongoing patient registry was culled to identify 373 patients that received bone marrow concentrate injections for the treatment of 424 osteoarthritic knee joints. The clinical scales for these patients were assessed at baseline and then tracked post-procedure at 1, 3, 6 and 12 months, and annually thereafter. Tracked outcomes included the numeric pain scale; a lower extremity functional questionnaire; an International Knee Documentation Committee scale; and a subjective improvement rating scale. Using pain and functional outcome measures, a receiver operating characteristic analysis was used to define an optimal clinical outcome threshold at which bone marrow nucleated cell count could be divided into either a lower or higher cell count group within a treatment protocol.


The lower and higher cell count groups were defined using a threshold of 4 × 108 cells. There were 224 and 185 knee joints treated in the lower (≤4 × 108) and higher (>4 × 108) cell count groups respectively. Most joints were diagnosed with early stage knee osteoarthritis. Both the lower and higher cell count groups demonstrated significant positive results with the treatment for all of the pain and functional metrics. The higher cell count group reported lower post treatment numeric pain scale values, in comparison with the lower cell count group (1.6 vs. 3.2; P < 0.001). No significant differences were detected for the other metrics, however.


Improved function and reduced pain was observed in patients treated with a bone marrow concentrate protocol regardless of cellular dose; however, patients receiving a higher concentration of cells reported a better pain outcome in comparison with the lower dose group. These preliminary findings suggest that cell dose may be an important factor governing clinical outcomes in autologous bone marrow concentrate treatment of knee osteoarthritis. Further studies using a larger patient population may help elucidate these findings.

Peer Review reports


Osteoarthritis of the knee is a common and progressive joint disorder characterized by gradual deterioration of the articular cartilage and inflammation of the adjacent tissues. An estimated 9 million people in the United States suffer from symptomatic knee osteoarthritis, and depending on disease severity, management ranges from conservative treatment to surgical intervention, including total knee replacement (TKR) [1]. In recent years the number and cost of TKR has increased dramatically; from 305,000 procedures costing an average of $25,500 per surgery in 2001 to 610,000 procedures costing an average of $52,000 per surgery in 2012 [2]. TKR is associated with significant complications, including deep vein thrombosis and infection, as well as post-surgical joint stiffness and muscle atrophy [3, 4]. Other lower risk surgical procedures are available as stopgap measures prior to TKR, such as arthroscopic meniscectomy, but such procedures are demonstrably lacking in long-term efficacy when compared with sham control procedures [5].

Non-surgical approaches to treating knee osteoarthritis, such as percutaneous injection of biological substances (e.g. hyaluronic acid and platelet-rich plasma (PRP), and Bone marrow derived nucleated cells (BMNCs)), represent a lower cost and lower risk alternative to surgery [6]. Clinical studies of intra-articular injection of PRP or BMNCs into the knee have demonstrated reduction of pain and improved function [7, 8].

In humans, nucleated cells are isolated from the aspirate of bone marrow that is typically harvested from the superior iliac crest of the pelvis via trocar [9]. The composition of these nucleated cells is diverse including Mesenchymal Stem Cells (MSCs), Hematopoetic Stem Cells (HSCs), Monocyte Precursor cells, Macrophages, T cells, B cells, Dendritic Antigen Presenting Cells, Natural Killer Cells and Neutrophils [1012]. The action of these cells, acting both in isolation and symbiotically, once introduced into arthritic joints may help improve pain and function by replenishing damaged joint structures and providing a mediation of catabolic immune response, thus alleviating the symptoms and progression of the disease [12, 13].

MSCs are multipotent with the capacity to differentiate into various cell types from a mesodermal origin including cartilage, ligament, tendon, bone and fat [13]. Prior animal studies have demonstrated cartilage healing after joint osteoarthritis treatment with high dose expanded MSCs [1416]; however, Bone Marrow Concentrate (BMC) contains only a fraction of the MSCs described in these studies [17]. Interestingly, other studies have demonstrated comparable results with direct application of BMNCs without the isolation and expansion of MSCs [10]. These observations raise numerous questions including to what extent the other nucleated cells in the bone marrow affect tissue healing and whether there is an optimal BMC cell dose for the most efficacious treatment of joint osteoarthritis.

BMC protocols have been employed throughout the growing field of Regenerative Medicine in the treatment of osteoarthritis [8, 13]. These protocols often contain PRP or Platelet lysate (PL), which enhance both bone marrow and adipocyte derived MSCs proliferation when used as a culture medium in vitro [18, 19]. Laden with growth factors [13], which have been show to influence MSC differentiation toward chondrocytes [19, 20], PRP and PL increase the activity of MSCs.

There is significant variability in MSC content of the bone marrow from person to person [21], hence providing the correct autologous dose to a joint could be important. Traditionally colony forming units have been used as a proxy for MSC dose [22, 23], but this technique can’t be used in real time to adjust the amounts injected at the bedside as it requires several days of culture for colony formation. Alternatively, flow cytometry could be used, but this technology is expensive and takes a dedicated lab staff to run, and is thus impractical for office based, clinical use [24]. Nucleated cell count may be a solution for office based use as the count is easy to obtain at the bedside and several studies show that it is a reasonable proxy for MSC dose [25, 26]. In addition, having nucleated cell count data readily available before cells are re-injected into a joint could allow for adjustments of the dose.

In the present observational study using registry data, we examine the effectiveness of using a specific lower and higher BMNC dose injection protocol for the treatment of knee osteoarthritis. We also analyze the clinical outcome differences between the two doses.


Setting and participants

Outcomes data for this study was derived from a previously reported treatment registry of patients receiving autologous MSCs, BMC, or PRP for the treatment of joint disorders including among others, knee, hip, and shoulder joints [25, 2730]. The registry protocol was approved by a Institutional Review Board (HHS OHRP #IRB00002637). All subjects (or their guardians if they were under 18 years old) were required to undergo an informed consent process and sign an informed consent form before they enter the registry. In the current study, patients presenting to one clinic with symptomatic knee osteoarthritis, as determined by Magnetic Resonance Imaging (MRI), and knee pain complaints with decreased function were included for analysis. Knee osteoarthritis on MRI was defined as any abnormalities of the cartilage, bone, or meniscus for example: chondral or osteochondral defects, chondral loss, meniscus tears, bone marrow lesions, joint space narrowing, bone marrow lesions, or bone spurring. All MRI images were read, and severity grades were determined by treating physicians. All patients who were treated with BMC injections, combined with PRP and PL, were included in the study.

Patients enrolled in the treatment registry were prospectively followed using an electronic system, ClinCapture software (Clinovo Clinical Data Solutions, Sunnyvale, California) that generates an automated, post-treatment, questionnaire for evaluation at 1, 3, 6 and 12 months, and annually thereafter. Registry staff compiled all data, as well as contacted patients that failed to respond to the electronic survey.

Procedure description

A detailed description of BMC aspiration and injection procedures has been previously published [31]. Briefly, two weeks prior to undergoing BMC injection, patients were restricted from use of corticosteroids and non-steroidal anti-inflammatory drugs (NSAIDs) as this reduces healing. On the day of the procedure, approximately 10–15 cc of whole bone marrow aspirate was harvested from 6 to 8 bone sites (approximately 3–4 on each side) of the patients’ Posterior Superior Iliac Crest. Under sterile conditions, the whole bone marrow aspirate was sequentially centrifuged, and resultant nucleated cells contained within were isolated for injection. Concomitantly, patient-derived heparinized venous blood was used to isolate PRP, and prepare PL by freeze-thawing the PRP. Using ultrasound or fluoroscopy to guide needle placement, a nucleated cell preparation of varying dose, contained within varying volume, and standardized volumes of PRP and PL were delivered to both the intra-articular space as well as painful or damaged structures of the knee. For example, if a meniscus tear was detected upon MRI or ultrasound examination, then in addition to the intra-articular space, the meniscus tear area was also injected with the nucleated cell preparation.

Post-operatively, patients with one compartment dominant disease (i.e. a single site within the knee joint) were provided with activity instructions and fitted with an off-loader brace that was to be worn for duration of 6 weeks for all weight bearing activity. Patients with patella-femoral compartment disease were fitted with a patella brace and instructed to avoid bearing full weight on the treated extremity for several days, then resume full weight bearing as soon as feasible. Full activity was gradually implemented over a 6-week period. Although patients were encouraged to undergo physical therapy, it was not required nor controlled.

Nucleated cell dose

The predictor of interest in this study was the total nucleated cell count contained in the bone marrow aspirate. The number of nucleated cells in each patient sample was manually counted under a microscope (National Optical, Schertz, TX) using a hemocytometer (Reichert Bright-Line, Hausser Scientific, Horsham, PA). Prior to counting, red blood cells were lysed by diluting 5 μL of sample in 995 μL of sterile, distilled water (Life Technologies, Grand Island, NY). Each sample was counted four times and the average calculated. The total nucleated cell count for injection was determined by multiplying the dilution factor, the volume of the hemocytometer, and the final volume of the sample.


An examination of potentially confounding variables included: age, gender, BMI, severity of disease, and follow-up time in months. The baseline severity of osteoarthritis, as well as candidacy for the procedure, was graded by the treating physician using the Kellgren-Lawrence (KL) scale, where KL1 represented a “Good” candidacy grade, KL2 represented a “Fair” grade, and KL3 and 4 signified a “Poor” grade [32]. These categories were based on the imaging-determined disease severity [33]. This included the use of MRIs and AP standing radiography. BMI and follow-up time in months were examined as continuous numeric variables.

Outcomes of interest

In this study, four clinical scales were used to measure outcomes of pain or functional improvement. The follow-up duration for each scale was measured as a score reported by the patient beginning from the date of the procedure (i.e. BMC injection) to the date of the last follow-up.

The NPS was used to assess knee pain based on a one-item questionnaire that assesses patients’ physical pain in the affected area using an eleven scoring levels ranging from 0 (no pain) to 10 (most severe pain) [34]. The LEFS consists of a 20 item measure of daily activities and function based on a five-point Likert scale [35], where difficulty levels for each item are classified into: extreme difficulty or inability to perform activity (0 point), quite a bit of difficulty (1 point), moderate difficulty (2 points), a little bit of difficulty (3 points), and no difficulty (4 points). The total LEFS score is the sum of points for the twenty items and ranges from 0 (i.e. minimum functional activity) to 80 points (i.e. maximum functional activity). The International Knee Documentation Committee scale (IKDC) is another subjective questionnaire consisting of 18 items that measure knee symptoms, function and sport activities [36]. The total IKDC score ranges from 0 to 100, with higher scores reflecting a better condition. The IKDC form includes three main sections: symptom, sport activities, and function. The three sections are combined in one total score. The subjective percentage improvement rating scale was based on the following question: “Compared to your condition prior to the procedure, what percent difference have you seen in your condition?” The patients’ response ranged from −100 % (denoting “worst condition”) to 100 % (indicating “best condition”). A score of zero would indicate no change.

Statistical analysis

A receiver operating characteristics (ROC) curve analysis was used to determine the optimal threshold for dichotomizing cell counts into higher and lower cell count groups. Using a composite variable based on the NPS and LEFS (see Outcomes of Interest), a ROC curve analysis identified the level at which sensitivity and specificity for composite pain and functional improvement was maximized. To avoid having two different cut-points for the cell count, a composite variable of functional improvement and pain was chosen for the analysis rather than separately evaluating pain and functional improvement. Any improvement to the composite variable was defined as achieving the minimum important differences in both the NPS and LEFS, where a minimum important difference was indicated by a 9-point increase on the LEFS and a 2-point decrease on the NPS [34, 35]. A lack of improvement was defined as a failure to achieve any of these changes.

Mean and standard deviation of the baseline and follow-up scores are described, as well as the differences between these two scores. Intra-group changes from the baseline were analyzed using the signed rank test. An analysis of covariance (ANCOVA) was used to estimate the adjusted means, controlling for the associated baseline score and potential confounding factors. The same multivariate analysis was conducted on the four outcome (dependent) variables including: NPS, LEFS, IKDC and subjective improvement rating scale. ANCOVA models were tested for the homogeneity of variance, homogeneity of regression, and normal distribution of residuals. Homogeneity of variances was tested using Levene’s tests, and homogeneity of regression was tested by introducing interaction terms to the models and testing their significance. Models’ residuals were plotted using histograms and Q-Q plots, and scatter plots for residual and predicted values were also created. Plots were examined for normality, presence of outliers, or unusual patterns. Spearman correlation was also used to test the correlation between cell doses as a continuous variable with changes in clinical scales’ scores.

An analysis was also performed to assess the differences in baseline characteristics between patients who responded to the follow-up surveys and those who did not. This analysis included only procedures that had available data for each respective clinical scale. Wilcoxon rank sum, chi square, or Fisher exact tests were used when appropriate. Data were analyzed using SAS 9.4 software (SAS Institute Inc. 2014: Cary, NC). Statistical significance was considered at p-value ≤ 0.05. Post-hoc power analysis was performed using G*Power 3.1 software.


Between the periods of August 2010 and February 2014, a total of 373 patients received treatment in 424 knee joints. Cell count information was available for 409 of the procedures. Optimal sensitivity and specificity for pain and functional improvement was estimated via ROC at 4 × 108 cells, and served as the value to discriminate between the higher and lower cell count groups (Fig. 1). There were 185 procedures (n = 170 patients) in the higher cell count group (>4 × 108 cells), and 224 procedures (n = 188 patients) in the lower cell count group (≤4 × 108 cells). Based on the radiological data, 55.6 and 59.4 % of the lower and higher cell count groups had early stage knee osteoarthritis (KL grade 1) (Table 1). The distribution of cell counts is presented in Fig. 2, and baseline characteristics of the higher and lower cell count groups are reported in Table 1.

Fig. 1

Sensitivity and specificity for composite pain and functional improvement as predicted by the nucleated cell count and examined by the receiver operating characteristics curve analysis

Table 1 Baseline characteristics and the statistical significance of the differences between the lower and higher cell count groups (NC = nucleated cells, SD = standard deviation, KL = Kellgren-Lawrence)
Fig. 2

Nucleated cell count of the study population. Lower nucleated cell count group was categorized as ≤ 4 × 108 cells; whereas in the higher cell count group, there were > 4 × 108 nucleated cells

The total number of participants responding to the NPS, LEFS and IKDC questionnaires was 116, 94, and 47, respectively; these frequencies represent subjects who had available baseline and follow-up data for the respective clinical scale. There were no significant differences between the responders and non-responders to questionnaires with regard to demographics or baseline metrics. A reduction in pain following treatment was statistically significant in both treatment groups, as the NPS decreased by 1.5 and 0.9 in the higher and lower cell count groups, respectively (P < 0.001 and P = 0.006). There were positive changes in both the LEFS and IKDC scales in both groups as well; the LEFS scale improved by 8.9 and 4.8 (P = 0.002 and 0.001), and the IKDC improved by 14.2 and 19.7 (P < 0.001 and P = 0.004), for the higher and lower cell count groups, respectively.

After adjusting for potential confounding factors (see Tables 2, 3), the outcomes for the higher and lower cell count groups were compared. A difference in the NPS means between the two cell count groups was statistically significant (higher cell count group mean = 1.6, versus lower cell count group mean = 3.2; P < 0.001). In contrast, a comparison between the adjusted means for LEFS and IKDC scores indicated no significant differences between the higher and lower cell count groups. Spearman correlation test showed that only changes in NPS scores were correlated with cell dose as a continuous variable with a borderline statistical significance (correlation coefficient = −0.13, P = 0.081). Other clinical scales did not show significant correlation with cell dose.

Table 2 Baseline and follow-up means of the clinical scales, significance of intra-group changes and follow-up duration in months (NC = nucleated cells, SD = standard deviation, LEFS = lower extremity functional scale, NPS = numeric pain scale, IKDC = international knee documentation committee scale, P-values are for intra-group changes, improvement rating = percentage improvement rating scale)
Table 3 Means of the last follow-up scores of clinical scales adjusted for baseline score of the respective scale, follow-up time, age, BMI, gender, and severity grade (NC = nucleated cells, SE = standard error, LEFS = lower extremity functional scale, NPS = numeric pain scale, IKDC = international knee documentation committee scale, improvement rating = percentage improvement rating scale)


Consistent with the previously published results from our group and others, significant improvement of pain and function was observed in osteoarthritis knee joints following injection with BMC at both higher and lower doses of nucleated cells [8, 37]. In both groups, most knee joints were diagnosed with early-stage knee osteoarthritis. Although a higher cell count dose was associated with a greater reduction in pain, there were no significant differences in functional improvement including the LEFS and IKDC, and the subjective improvement rating scale following injection with either a higher or lower cell count.

Although absolute difference in pain outcomes between higher and lower doses was less than two points, the minimum important difference defined in the literature; the NPS score in the higher dose group was 50 % lower than that in the lower dose group, a difference which is considered clinically significant [38] especially given the fact that the comparison is made between two low means; therefore we do not expect to see a high absolute difference in scores despite the highly significant difference as a percentage.

Prior studies of cell dose and therapeutic efficacy of the BMC injectate have been inconclusive. In animal studies, intra-articular injection of either BMC (lower MSC content) or culture-expanded MSCs (higher MSC content) facilitated regeneration of damaged cartilage; however, neither approach showed any superiority in therapeutic efficacy [39]. Clinical studies in humans have demonstrated mixed results, with one study indicating the superiority of higher concentrations of MSCs at repair of cartilage and meniscus injury [40], and another study indicating greater efficacy at lower cell concentrations of culture-expanded allogeneic cells [41]. The findings from the latter study may be explained by a greater host immune response resulting from the higher-doses of allogeneic cells [26].

Previous work investigating MSC concentration in the reduction of discogenic low back pain, revealed similar findings with patients receiving higher cell concentration intra-discal injections reporting a statistically significant greater reduction in pain compared to lower cell concentrations [23]. The findings of the present study are unique; prior studies have described the use of BMC for treatment of symptomatic osteoarthritis, but there are none that have examined a cell dose response, or identified an optimal threshold count of nucleated cells for maximizing clinical outcome [31].

Conceptually, it makes sense that a higher BMNC count equates to better pain relief than a lower cell count. Nucleated cell count is a proxy for the total number of MSCs, and MSCs are the cells that contribute to regeneration of intra-articular cartilage [25, 42]. Unlike studies that have focused on culture expanded MSCs, the number of these cells in BMC is much smaller [24]. Hence, dose may be more critical in some patients with poor MSC counts in bone marrow, which is common in older patients [21]. Additionally, BMC constituents including hematopoietic stem cells, T-lymphocytes, B-lymphocytes, monocytes, macrophages, epithelial progenitor cells and platelets, are all capable of producing growth factors and cytokines that together may support a microenvironment that promotes proliferation and functional differentiation of MSCs as well as cartilage repair [43]. For example, co-culture of MSCs with Monocytes has been shown to increase chondrogenic differentiation capacity [12]. Finally, MSCs have been shown to reduce pain in animal models by the release of TGF-beta [44].

It is important to note that the observed treatment’s effect may be attributed to the platelet component of injections; PRP and PL have been shown in numerous studies to improve the symptoms associated with mild-moderate knee osteoarthritis [4547]. However, the clinical efficacy of PRP therapy is transient, and relief from pain and function improvement declines to baseline between 6 and 24 months after treatment [48, 49]. Further, the efficacy of PRP therapy is limited in moderate and severe osteoarthritis, versus mild osteoarthritis [7, 50, 51]. Finally, the significant difference in pain score associated with the higher nucleated cell group in this study reveals that varying MSC dose, within a standardized protocol of platelet injections, has an impact on treatment outcome.

Limitations of the present study are typical of registry studies; there was no placebo control group, and there was no randomization of the patients into the lower and higher cell dose groups. As a result it is possible that uncontrolled for confounding factors or even a placebo effect may account for the results. It is unlikely that the positive results observed for both cell count groups were due to response bias; the analysis of the non-responders indicated no significant differences with regard to age, gender, weight, or baseline severity in comparison with the responders. Also the lack of significance of the differences in the functional outcome scales may be due to limited statistical power. Another limitation of this study is that the ROC analysis and ANCOVA models were performed on data subsets obtained from the same population. ROC analysis was performed on subjects who had available baseline and follow-up scores for both LEFS and NPS scales. ANCOVA models included subjects who had available data for all covariates, in addition to the baseline and follow-up scores of the respective outcome scale. Therefore, future research on different populations is needed to confirm our study’s findings. Sufficiently powered randomized placebo-controlled trials are needed to validate and expand on these preliminary results.


Improved function and reduced pain was observed in patients treated with BMC injectate regardless of cellular dose; however, patients receiving a higher concentration of cells reported a better pain outcome in comparison with the lower dose group. These findings indicate that cell dose may be a factor governing clinical outcomes in autologous BMC treatment of knee osteoarthritis. Further studies using randomized and placebo-controlled design are needed.



Analysis of covariance


Bone marrow concentrate


Bone marrow derived nucleated cells


Hematopoetic stem cells


International knee documentation committee




Lower extremity function scale


Mesenchymal stem cell


Magnetic resonance imaging


Numeric pain scale


Non-steroidal anti-inflammatory drug


Platelet lysate


Platelet-rich plasma


Receiver operating characteristic


Total knee replacement


  1. 1.

    Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H, Deyo RA, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum. 2008;58(1):26–35.

    PubMed  PubMed Central  Article  Google Scholar 

  2. 2.

    Agency for Healthcare Research and Quality. Nationwide Inpatient Sample (NIS), Healthcare Cost and Utilization Project (HCUP). 2014 July 17; Available from:

  3. 3.

    Schairer WW, Zhang AL, Feeley BT. Hospital readmissions after primary shoulder arthroplasty. J Shoulder Elbow Surg. 2014.

  4. 4.

    Urquhart DM, Hanna FS, Brennan SL, Wluka AE, Leder K, Cameron PA, et al. Incidence and risk factors for deep surgical site infection after primary total hip arthroplasty: a systematic review. J Arthroplasty. 2010;25(8):1216–22. e1-3.

    PubMed  Article  Google Scholar 

  5. 5.

    Sihvonen R, Paavola M, Malmivaara A, Itälä A, Joukainen A, Nurmi H, et al. Arthroscopic partial meniscectomy versus sham surgery for a degenerative meniscal tear. N Engl J Med. 2013;369(26):2515–24.

    CAS  PubMed  Article  Google Scholar 

  6. 6.

    Dhillon MS, Behera P, Patel S, Shetty V. Orthobiologics and platelet rich plasma. Indian J Orthop. 2014;48(1):1–9.

    PubMed  PubMed Central  Article  Google Scholar 

  7. 7.

    Filardo G, Kon E, Di Martino A, Di Matteo B, Merli ML, Cenacchi A, et al. Platelet-rich plasma vs hyaluronic acid to treat knee degenerative pathology: study design and preliminary results of a randomized controlled trial. BMC Musculoskelet Disord. 2012;13:229.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  8. 8.

    Centeno C, Pitts J, Al-Sayegh H, Freeman M. Efficacy of autologous bone marrow concentrate for knee osteoarthritis with and without adipose graft. Biomed Res Int. 2014;2014:370621.

    PubMed  PubMed Central  Article  Google Scholar 

  9. 9.

    Williams AR, Hare JM. Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease. Circ Res. 2011;109(8):923–40.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  10. 10.

    Zhang Y, Wang F, Chen J, Ning Z, Yang L. Bone marrow-derived mesenchymal stem cells versus bone marrow nucleated cells in the treatment of chondral defects. Int Orthop. 2012;36(5):1079–86.

    PubMed  Article  Google Scholar 

  11. 11.

    Ikehara A, Maeda H, Kimura T, Saito S, Ochiai AA. Bone marrow-derived macrophages are associated with androgen modulated prostate regeneration. Prostate. 2012;72(1):1–11.

    CAS  PubMed  Article  Google Scholar 

  12. 12.

    Sesia SB, Duhr R, Medeiros, da Cunha C, Todorov A, Schaeren S, Padovan E, et al. Anti-inflammatory/tissue repair macrophages enhance the cartilage-forming capacity of human bone marrow-derived mesenchymal stromal cells. J Cell Physiol. 2015;230(6):1258–69.

    CAS  PubMed  Article  Google Scholar 

  13. 13.

    Bashir J, Sherman A, Lee H, Kaplan L, Hare JM. Mesenchymal stem cell therapies in the treatment of musculoskeletal diseases. PM R. 2014;6(1):61–9.

    PubMed  Article  Google Scholar 

  14. 14.

    Grigolo B, Lisignoli G, Desando G, Cavallo C, Marconi E, Tschon M, et al. Osteoarthritis treated with mesenchymal stem cells on hyaluronan-based scaffold in rabbit. Tissue Eng Part C Methods. 2009;15(4):647–58.

    CAS  PubMed  Article  Google Scholar 

  15. 15.

    Horie M, Sekiya I, Muneta T, Ichinose S, Matsumoto K, Saito H, et al. Intra-articular Injected synovial stem cells differentiate into meniscal cells directly and promote meniscal regeneration without mobilization to distant organs in rat massive meniscal defect. Stem Cells. 2009;27(4):878–87.

    CAS  PubMed  Article  Google Scholar 

  16. 16.

    Lee KB, Hui JH, Song IC, Ardany L, Lee EH. Injectable mesenchymal stem cell therapy for large cartilage defects--a porcine model. Stem Cells. 2007;25(11):2964–71.

    PubMed  Article  Google Scholar 

  17. 17.

    Hernigou P, Poignard A, Beaujean F, Rouard F. Percutaneous autologous bone-marrow grafting for nonunions. Influence of the number and concentration of progenitor cells. J Bone Joint Surg Am. 2005;87(7):1430–7.

    PubMed  Article  Google Scholar 

  18. 18.

    Zhang YZ, Da WM. Experimental study of platelet-rich plasma optimizing mesenchymal stem cells culture. Zhonghua Xue Ye Xue Za Zhi. 2006;27(6):403–5.

    CAS  PubMed  Google Scholar 

  19. 19.

    D'Esposito V, Passaretti F, Perruolo G, Ambrosio MR, Valentino R, Oriente F, et al. Platelet-rich plasma increases growth and motility of adipose tissue-derived mesenchymal stem cells and controls adipocyte secretory function. J Cell Biochem. 2015.

  20. 20.

    Augustyniak E, Trzeciak T, Richter M, Kaczmarczyk J, Suchorska W. The role of growth factors in stem cell-directed chondrogenesis: a real hope for damaged cartilage regeneration. Int Orthop. 2015;39(5):995–1003.

    PubMed  Article  Google Scholar 

  21. 21.

    Bouwmeester W, Fechter MM, Heymans MW, Twisk JW, Ebeling LJ, Brand A, et al. Prediction of nucleated cells in bone marrow stem cell products by donor characteristics: a retrospective single centre analysis. Vox Sang. 2010;98(3 Pt 1):e276–83.

    CAS  PubMed  Article  Google Scholar 

  22. 22.

    Premer C, Blum A, Bellio MA, Schulman IH, Hurwitz BE, Parker M, et al. Allogeneic mesenchymal stem cells restore endothelial function in heart failure by stimulating endothelial progenitor cells. EBioMedicine. 2015;2(5):467–75.

    PubMed  PubMed Central  Article  Google Scholar 

  23. 23.

    Pettine KA, Murphy MB, Suzuki RK, Sand TT. Percutaneous injection of autologous bone marrow concentrate cells significantly reduces lumbar discogenic pain through 12 months. Stem Cells. 2015;33(1):146–56.

    CAS  PubMed  Article  Google Scholar 

  24. 24.

    Mundy LN, Ishihara A, Wellman ML, Bertone AL. Evaluation of the ability of a gravitational filtration system to enhance recovery of equine bone marrow elements. Am J Vet Res. 2015;76(6):561–9.

    PubMed  Article  Google Scholar 

  25. 25.

    Centeno CJ, Busse D, Kisiday J, Keohan C, Freeman M, Karli D. Increased knee cartilage volume in degenerative joint disease using percutaneously implanted, autologous mesenchymal stem cells. Pain Physician. 2008;11(3):343–53.

    PubMed  Google Scholar 

  26. 26.

    Li P, Li SH, Wu J, Zang WF, Dhingra S, Sun L. Increased knee cartilage volume in degenerative joint disease using percutaneously implanted, autologous mesenchymal stem cells. Pain Physician. 2008;11(3):343–53.

    Google Scholar 

  27. 27.

    Centeno CJ, Busse D, Kisiday J, Keohan C, Freeman M, Karli D. Regeneration of meniscus cartilage in a knee treated with percutaneously implanted autologous mesenchymal stem cells. Med Hypotheses. 2008;71(6):900–8.

    CAS  PubMed  Article  Google Scholar 

  28. 28.

    Centeno CJ, Schultz JR, Cheever M, Freeman M, Faulkner S, Robinson B, et al. Safety and complications reporting update on the re-implantation of culture-expanded mesenchymal stem cells using autologous platelet lysate technique. Curr Stem Cell Res Ther. 2011;6(4):368–78.

  29. 29.

    Centeno C, Schultz JR, Cheever M, Freeman M, Robinson B, Faulkner SJ. A Case Series of Percutaneeous Treatment of Non-Union Fractures with Autologous, Culture Expanded, Bone Marrow Dervied, Mesenchymal Stem Cells and Platelet Lysate. Journal of Bioengineering & Biomedical Science. 2011;Special Issue, S2-007.

  30. 30.

    Centeno CJ, Freeman MD. Percutaneous injection of autologous, culture-expanded mesenchymal stem cells into carpometacarpal hand joints: a case series with an untreated comparison group. Wiener Medizinische Wochenschriff. 2014;164(5-6):83–7.

  31. 31.

    Centeno C, Pitts J, Al-Sayegh H, Freeman M. Efficacy of Autologous Bone Marrow Concentrate for Knee Osteoarthritis with and without Adipose Graft. BioMed Research International, 2014. 2014: p. 9. Epub 2014 Sep 7.

    Article  Google Scholar 

  32. 32.

    Kellgren JH, Lawrence JS. Radiological assessment of osteo-arthrosis. Ann Rheum Dis. 1957;16(4):494–502.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  33. 33.

    Sowers M, Karvonen-Gutierrez CA, Jacobson JA, Jiang Y, Yosef M. Associations of anatomical measures from MRI with radiographically defined knee osteoarthritis score, pain, and physical functioning. J Bone Joint Surg Am. 2011;93(3):241–51.

    PubMed  PubMed Central  Article  Google Scholar 

  34. 34.

    Childs JD, Piva SR, Fritz JM. Responsiveness of the numeric pain rating scale in patients with low back pain. Spine (Phila Pa 1976). 2005;30(11):1331–4.

    Article  Google Scholar 

  35. 35.

    Binkley JM, Stratford PW, Lott SA, Riddle DL. The Lower Extremity Functional Scale (LEFS): scale development, measurement properties, and clinical application. North American Orthopaedic Rehabilitation Research Network. Phys Ther. 1999;79(4):371–83.

    CAS  PubMed  Google Scholar 

  36. 36.

    Collins NJ, Misra D, Felson DT, Crossley KM, Roos EM. Measures of knee function: International Knee Documentation Committee (IKDC) Subjective Knee Evaluation Form, Knee Injury and Osteoarthritis Outcome Score (KOOS), Knee Injury and Osteoarthritis Outcome Score Physical Function Short Form (KOOS-PS), Knee Outcome Survey Activities of Daily Living Scale (KOS-ADL), Lysholm Knee Scoring Scale, Oxford Knee Score (OKS), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), Activity Rating Scale (ARS), and Tegner Activity Score (TAS). Arthritis Care Res (Hoboken). 2011;63 Suppl 11:S208–28.

    Article  Google Scholar 

  37. 37.

    Bornes TD, Adesida AB, Jomha NM. Mesenchymal stem cells in the treatment of traumatic articular cartilage defects: a comprehensive review. Arthritis Res Ther. 2014;16(5):432.

    PubMed  PubMed Central  Article  Google Scholar 

  38. 38.

    Farrar JT, Young Jr JP, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 2001;94(2):149–58.

    CAS  PubMed  Article  Google Scholar 

  39. 39.

    Song F, Tang J, Geng R, Hu H, Zhu C, Cui W, et al. Comparison of the efficacy of bone marrow mononuclear cells and bone mesenchymal stem cells in the treatment of osteoarthritis in a sheep model. Int J Clin Exp Pathol. 2014;7(4):1415–26.

    PubMed  PubMed Central  Google Scholar 

  40. 40.

    Wang W, Cao W. Treatment of osteoarthritis with mesenchymal stem cells. Sci China Life Sci. 2014..

  41. 41.

    Vangsness Jr CT, Farr 2nd J, Boyd J, Dellaero DT, Mills CR, LeRoux-Williams M, et al. Adult human mesenchymal stem cells delivered via intra-articular injection to the knee following partial medial meniscectomy: a randomized, double-blind, controlled study. J Bone Joint Surg Am. 2014;96(2):90–8.

    PubMed  Article  Google Scholar 

  42. 42.

    Singh A, Goel SC, Gupta KK, Kumar M, Arun GR, Patil H, et al. The role of stem cells in osteoarthritis: an experimental study in rabbits. Bone Joint Res. 2014;3(2):32–7.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  43. 43.

    Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284(5411):143–7.

    CAS  PubMed  Article  Google Scholar 

  44. 44.

    Chen G, Park CK, Xie RG, Ji RR. Intrathecal bone marrow stromal cells inhibit neuropathic pain via TGF-beta secretion. J Clin Invest. 2015.

  45. 45.

    Raeissadat SA, Rayegani SM, Hassanabadi H, Fathi M, Ghorbani E, Babaee M, et al. Knee Osteoarthritis Injection Choices: Platelet- Rich Plasma (PRP) Versus Hyaluronic Acid (A one-year randomized clinical trial). Clin Med Insights Arthritis Musculoskelet Disord. 2015;8:1–8.

    PubMed  PubMed Central  Google Scholar 

  46. 46.

    Gobbi A, Lad D, Karnatzikos G. The effects of repeated intra-articular PRP injections on clinical outcomes of early osteoarthritis of the knee. Knee Surg Sports Traumatol Arthrosc. 2014;23(8):2170–7.

    PubMed  Article  Google Scholar 

  47. 47.

    Lai LP, Stitik TP, Foye PM, Georgy JS, Patibanda V, Chen B, et al. Use of platelet-rich plasma in intra-articular knee injections for osteoarthritis: a systematic review. PM R. 2015;7(6):637–48.

    PubMed  Article  Google Scholar 

  48. 48.

    Pourcho AM, Smith J, Wisniewski SJ, Sellon JL. Intraarticular platelet-rich plasma injection in the treatment of knee osteoarthritis: review and recommendations. Am J Phys Med Rehabil. 2014;93(11 Suppl 3):S108–21.

    PubMed  Article  Google Scholar 

  49. 49.

    Tietze DC, Geissler K, Borchers J, Tietze DC, Geissler K, Borchers J. The effects of platelet-rich plasma in the treatment of large-joint osteoarthritis: a systematic review. Phys Sportsmed. 2014;42(2):27–37.

    PubMed  Article  Google Scholar 

  50. 50.

    Patel S, Dhillon MS, Aggarwal S, Marwaha N, Jain A. Treatment with platelet-rich plasma is more effective than placebo for knee osteoarthritis: a prospective, double-blind, randomized trial. Am J Sports Med. 2013;41(2):356–64.

    PubMed  Article  Google Scholar 

  51. 51.

    Filardo G, Kon E, DI Matteo B, DI Marino A, Sessa A, Merli ML, et al. Leukocyte-poor PRP application for the treatment of knee osteoarthritis. Joints. 2013;1(3):112–20.

    PubMed  Google Scholar 

Download references


Shawn Thayer participated in analyzing procedural data.

Author information



Corresponding author

Correspondence to Hasan Al-Sayegh.

Additional information

Competing interests

Dr. Christopher Centeno is a shareholder and director of Regenerative Sciences, LLC. Dr. Hasan Al-Sayegh is affiliated with the Centeno-Schultz Clinic and Regenerative Sciences, LLC. Dr. Jamil Bashir is a fellow training at The Centeno-Schultz Clinic. Dr. Shaun Goodyear has no competing interests. Dr. Michael Freeman has no competing interests.

Authors’ contributions

CC, HA, JB, SG and MF all participated in study design, data analysis and interpretation, and preparation of the manuscript. All authors read and approved the final manuscript.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Centeno, C.J., Al-Sayegh, H., Bashir, J. et al. A dose response analysis of a specific bone marrow concentrate treatment protocol for knee osteoarthritis. BMC Musculoskelet Disord 16, 258 (2015).

Download citation


  • Knee Osteoarthritis
  • Total Knee Replacement
  • International Knee Documentation Committee
  • Minimum Important Difference
  • Cell Dose